Drug Profile
Research programme: soluble interleukin-17 receptor C therapeutics - Merck Serono
Alternative Names: IL-17RC; IL-17RC - Merck Serono/ZymoGeneticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck Serono; ZymoGenetics
- Developer Merck Serono
- Class Interleukins; Proteins
- Mechanism of Action Interleukin 17 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 13 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
- 22 Apr 2009 Preclinical development is ongoing